Recent Data on Axi-Cel in Lymphoma
Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.
Source: onclive.com
Axi Cel News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Axi Cel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Axi Cel Today - Breaking & Trending Today
Choosing CAR T-cells as Third-line and Beyond Therapy for FL
Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.
Source: onclive.com
Dr Leslie on the Clinical Benefit of Axi-Cel in Elderly Patients With R/R LBCL
Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma.
Source: onclive.com
CAR T-cells as Third-line and Beyond Therapy for FL
Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.
Source: onclive.com
Axi-Cel Provides Sustained Response in High-Risk Large B-cell Lymphoma
Patients with high-risk large B-cell lymphoma experienced durable responses when treated with first-line axicabtagene ciloleucel, according to results from the phase 2 ZUMA-12 trial.
Source: onclive.com